Debrisoquine 4-hydroxylase activity is a prototype for genetic polymorphism in oxidative drug metabolism in humans; approximately 10% of Caucasian populations exhibit the poor metabolizer phenotype, and the clearance of at least 14 other drugs has been shown to be deficient in patients exhibiting this phenotype. Antibodies prepared to a cytochrome P-450 shown to be responsible for debrisoquine 4-hydroxylation in rats were found to inhibit the oxidation of debrisoquine and sparteine, encainide, and propranolol, three other drugs suggested to be associated with this phenotype, in human liver microsomes. The antibodies did not inhibit the oxidation of seven other cytochrome P-450 substrates. The antibodies recognized a single polypeptide of Mr 51,000 after combined sodium dodecyl sulfate/polyacrylamide electrophoresis and immunochemical staining of human liver microsomes. The intensity of this band was significantly correlated with debrisoquine 4-hydroxylase activity when liver microsomes from 44 organ donors were examined. Immunoprecipitation of in vitro translation products of total liver RNA revealed major electrophoretic bands corresponding to the cytochrome P-450 in rats and humans. The level of translatable mRNA coding for the debrisoquine-hydroxylating cytochrome P-450 was an order of magnitude less in human liver than in rat liver. The availability of these antibodies provides a biochemical basis for further basic and clinical studies on the role of a particular cytochrome P-450 polymorphism in humans.
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Genetic polymorphisms contribute in part to the large interindividual differences observed in the oxidation and conjugation of drugs and other compounds (1) (2) (3) . Approximately 10% of Caucasians are phenotypic poor metabolizers of the anti-hypertensive drug debrisoquine; these individuals are genotypic homozygous recessive at an autosomal genetic locus controlling the formation of 4-hydroxydebrisoquine, a major urinary metabolite in phenotypic extensive metabolizers (4, 5) . Studies with human liver microsomes suggest that poor metabolizers of debrisoquine lack the particular P-450 form that hydroxylates the drug in normal individuals (6) .
One clinical consequence of debrisoquine hydroxylation deficiency is that poor metabolizers are more sensitive to the hypotensive effects of debrisoquine (7) . Moreover, the oxidative metabolism of at least 14 other drugs is impaired in these individuals, suggesting a functional deficiency of one or more P-450 enzymes responsible for the oxidation of a large group of compounds (8) . Consequently, patients deficient in debrisoquine hydroxylation can be especially sensitive to the therapeutic or toxic effects of several other drugs because the parent compound is either poorly eliminated by metabolism or shunted to a secondary metabolic pathway, which produces greater amounts of a normally minor but toxic metabolite (9) . Deficient metabolizers of debrisoquine can also respond poorly to drugs that have pharmacologically active metabolites (10) . The phenotype of debrisoquine hydroxylation might also influence the ability of an individual to activate or detoxicate carcinogens and other toxic compounds if the P-450 isozyme controlled by the debrisoquine hydroxylation locus contributes to their metabolism (11) .
Using the rat as a model of genetic polymorphism in oxidative drug metabolism, we recently purified to electrophoretic homogeneity an isozyme of cytochrome P-450 from SpragueDawley rat liver with high catalytic activity toward debrisoquine (12) . Antibodies raised to this P-450, designated as P-45OUT-H, were used in immunochemical studies to demonstrate that P-45OUT-H is responsible for nearly all of the debrisoquine 4-hydroxylase activity in rat liver microsomes and that the female DA strain rat, which is a phenotypic poor metabolizer of debrisoquine (13) , has <5% the level of P-450UTH found in Sprague-Dawley rat liver.
To characterize the P-450 in human liver responsible for debrisoquine hydroxylation, antibodies raised to the rat P-450UT-H were examined for cross-reactivity toward human liver microsomal P-450s. In this report, we describe the association between levels of an immunoreactive P-450 and debrisoquine 4-hydroxylase activity among 44 different human liver samples as well as the effects of anti-P-45OUTH on 11 different mixed function oxidase activities in human liver. In addition, in vitro translation of the mRNAs coding for the responsible P-450s has been carried out in rat and human liver.
MATERIALS AND METHODS
Liver samples were obtained through the Nashville Organ Procurement Agency from organ donors who met accidental deaths; samples were perfused and chilled to 0°C within 30 min after death, cut into small (1-6 cm3) portions, which were frozen quickly in liquid N2, and stored at -70°C (14) . Microsomes were prepared as described (14) and stored at -20°C prior to use. P-45OUT-H was purified from rat liver as described elsewhere and antibodies were raised in rabbits (12) .
Immunoelectrophoresis was carried out as described (12, 15) , except that Zeta-probe blotting membranes (Bio-Rad) were used in place of nitrocellulose paper. In the cases in which quantitation was done, 0.2 ug of horse liver alcohol dehydrogenase (Boehringer Mannheim) was added to each electrophoresis lane and a 1:200 dilution of rabbit anti-alcohol dehydrogenase was added to the anti-P-450UTH antisera
(1:50 dilution) used to develop the blots. The ratio of the intensity of the alcohol dehydrogenase band to the P-450
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450UT-H to normalize the data.
Immunoinhibition studies were carried out as described elsewhere (12) . Acetanilide hydroxylase (15) , aniline 4-hydroxylase (15), 7-ethoxycoumarin O-deethylase (15), debrisoquine 4-hydroxylase (12), propranolol 4-hydroxylase (12), mephenytoin 4-hydroxylase (16) , and encainide O-demethylase (12) assays were carried out as described elsewhere. dBenzphetamine N-demethylase, aminopyrine N-demethylase, and ethylmorphine N-demethylase activities were assayed as described (15) with fluorimetric determination of released HCHO (17) . Oxidation of (-)sparteine to A5-dehydrosparteine was assayed as described (18); A5-dehydrosparteine was synthesized according to Leonard et al. (19) .
Total hepatic RNA was isolated as described elsewhere (20) and translated in a rabbit reticulocyte translation system (Bethesda Research Laboratories) with [35S]methionine. Immunoprecipitated translation products (21) were electrophoresed in sodium dodecyl sulfate/polyacrylamide (7.5%) gels and visualized by fluorography.
RESULTS
Immunoinhibition of Enzyme Activity. Although previous work suggested that the rat might not be a completely appropriate model for genetic deficiency of debrisoquine 4-hydroxylase, we examined the ability of anti-rat P-45OUT-H to inhibit this activity in human liver microsomes. The antibody was able to inhibit >90% of the activity in preparations derived from three different patients (Fig. lA) .
Poor metabolizers of debrisoquine also exhibit impaired metabolism of sparteine, encainide, and propranolol (10, 18, 22) . Further, in vitro steady-state kinetic studies suggest that debrisoquine 4-hydroxylation and sparteine A5-oxidation are catalyzed by the same enzyme (23) . Anti-P-450UT-H nearly completely inhibited sparteine A5-oxidation in microsomes prepared from three different patients (Fig. 1B) . Encainide O-demethylase and propranolol 4-hydroxylase activities were inhibited to the extent of 50-80% among three patients ( Fig. 1 C and D) .t In no case did the IgG fraction prepared from pre-immune antisera show significant inhibition ( Fig.   1 ). The titer for inhibition was similar in human and rat microsomes (12) , and several rabbit and goat antibody preparations had similar inhibitory properties.
The same antibody preparation used for the experiments in Fig. 1 did not inhibit acetanilide hydroxylase, aniline 4-hydroxylase, 7-ethoxycoumarin O-deethylase, benzphetamine N-demethylase, or aminopyrine N-demethylase activity in three or four different human liver microsomal preparations (Fig. 2) . Ethylmorphine N-demethylase and mephenytoin 4-hydroxylase activities showed some inhibition but more than an order of magnitude less than in the cases presented in Fig. 1 .
Immunoelectrophoresis and Immunoquantitation. Though these antibodies were characterized in terms of specificity of inhibition of enzyme activities in humans and rats, further information was needed. Immunoblotting showed a single major band in rat liver microsomes, plus a minor band of greater mobility (Mr -30,000), which has contaminated some of the P-45OUT-H preparations (12) . Only a single band was observed with human liver microsomes (Fig. 3) . This band had a molecular weight (Mr 51,000) slightly less than that of rat P-45OUT-H (Mr 52,000), and its mobility was constant in all human liver preparations examined. Further, markedly less band intensity was observed in two preparations that exhibited low debrisoquine 4-hydroxylase activity (Fig. 3) .
These results suggested that the intensity of the blots might be correlated with debrisoquine 4-hydroxylation, as would be expected if the antigen reacting with anti-P-45OUT-H were responsible for most of this enzymatic activity. The correlation of debrisoquine 4-hydroxylase activity with the immunochemically estimated level of the P-450 form recognized by anti-P-45OUT-H is shown in Fig. 4 for 44 liver microsomal samples. Though this study is complicated by any potential deterioration that might occur before processing of samples to give low catalytic activity, the correlation coefficient for the plot was 0.63 (Fig. 4) . All samples analyzed in the experiment are included here. The correlation was significant at the P < 0.001 level in a two-tailed f-test (24) . The data were also analyzed by the Spearman rank correlation method (24), a non-parametric statistical test appropriate for such data, which are not normally distributed in a population. The correlation coefficient was 0.57, significant at the P < 0.001 level in a two-tailed f-test (24) . If one considers a blot intensity of '0.1 as indicative of a poor metabolizer, then all of these samples had debrisoquine 4-hydroxylase activities that were s8% of the highest activity. A number of points fall considerably below the line drawn by linear regression analysis; in addition to any deterioration of enzyme activity in the samples (or in vivo prior to clinical death), other factors that can affect these points include variation in levels of NADPH P-450 reductase and the presence of endogenous inhibitors. When blot intensity was compared to Immunoelectrophoresis of rat P-45OUT-H and four human liver microsomal preparations using anti-P-45OUT-H. Varying amounts of purified rat liver P-45OUT-H (0.5, 2.0, and 4.0 pmol) and liver microsomes prepared from patients 17, 18, 25, and 32 (20, 40 , and 100 ,ug of protein in each case) were electrophoresed in the indicated lanes. The resolved proteins were electrophoretically transferred to a Zeta-probe blotting membrane and the sheet was subsequently developed with an anti-P-450UT-H/horseradish peroxidase system (15) . The anode was at the bottom of the gel. The debrisoquine 4-hydroxylase activities of samples 17, 18, 25, and 32 were 0.0038, 0.0003, 0.072, and 0.070 nmol of product formed per min/mg of protein, respectively. positive correlation of debrisoquine 4-hydroxylase activity with immunochemical reactivity is consistent with the view that the P-450 under consideration is missing in poor debrisoquine metabolizers, the results do not prove this hypothesis and alternative explanations (e.g., P-450 microheterogeneity) cannot be ruled out at this point.
In Vitro Translations. Total RNA was isolated from the livers of rats and eight humans and translated in a rabbit reticulocyte system. Electrophoresis of imrhunoprecipitated translation products showed polypeptides corresponding to P-450UT-H and the analogous human P-450 (Fig. 5) . The antibodies also precipitated two uncharacterized higher molecular weight polypeptides in the human liver translations, and one of the samples (no. 60) contained a polypeptide of slightly lower molecular weight. However, we feel that the P-450s involved in debrisoquine hydroxylation are not synthesized as higher molecular weight precursors that require proteolytic processing. The high molecular weight polypeptides were not seen in immunoblotting of microsomes (Fig.  3 ). Since the antibodies should be precipitating all of the synthesized human liver polypeptide when immobilized protein A is used, these results also suggest that considerably less mRNA is available for translation of the debrisoquine-hydroxylating P-450 in humans than rats. Of 6.4 x 106 dpm of 35S recovered in the total translation products produced with rat liver RNA, 420 dpm were found associated with P-45OUT-H, or a frequency of roughly 6.6 x 10-5. The average frequency of translation of the corresponding P-450 from human liver RNA was 3.6 x 10-6; the levels of radioactivity (mean of 29 cpm above background) were too low to permit a useful comparison of translatable mRNA levels with debrisoquine 4-hydroxylase activity in the human liver samples. However, the mean level of debrisoquine 4-hydroxylase activity in these human liver samples was one-eighth that in the rat liver, consistent with the observation that the level of the corresponding translatable mRNA was an order of magnitude lower in human than rat liver. 
DISCUSSION
In this communication we report that an antibody preparation raised against a rat liver P-450 can selectively inhibit the in vitro metabolism of debrisoquine and 3 other drugs shown previously to be linked to debrisoquine 4-hydroxylation in clinical studies. The metabolism of seven other P-450 substrates could be dissociated by using this approach. Further, the specificity of the antibody with human liver microsomes was further demonstrated by immunoelectrophoresis, and a significant correlation between the immunoelectrophoretic data and debrisoquine 4-hydroxylase activity was demonstrated.
The similarity between rats and humans with regard to this form of P-450 is considerable, as demonstrated by the immunochemical work presented here and the activities of the purified rat P-45OUT-H toward debrisoquine, encainide, and propranolol (12) . This conservation between rats and humans is certainly more than the norm in the case of the P450s (14) . Further, these antibodies are probably the best biochemical probes of human polymorphism in oxidative drug metabolism available at this time. These antibodies can now be used to derive considerable knowledge at the in vitro level, which can be of use in studying metabolism of xenobiotics in humans. For instance, enzyme activity inhibition studies can be used to determine which other drugs that a person exhibiting the debrisoquine poor metabolizer phenotype would also oxidize in an unusual manner. Drugs in the process of development could also be screened for the possibility of altered metabolism in this sizeable segment of the population. Further, toxicants and carcinogens can be examined to determine expected patterns of biotransformation in phenotypic poor metabolizers. The antibodies should also be of use in isolating and characterizing the form of P-450 that metabolizes debrisoquine (and the other drugs) in humans. Finally, the antibodies may be useful in isolating the mRNA and preparing DNA probes to aid in understanding the regulation of the gene as well as to develop assays that can be used to screen patients using non-invasive methods.
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